Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

Leukemia

Volumn 25, Issue 5, 2011, Pages 781-791

  Evangelisti, C ^a   Ricci, F ^b   Tazzari, P ^b   Tabellini, G ^c   Battistelli, M ^d   Falcieri, E ^d,e   Chiarini, F ^a   Bortul, R ^f   Melchionda, F ^a   Pagliaro, P ^b   Pession, A ^a   McCubrey, J A ^g   Martelli, A M ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF TRIESTE   (Italy)

^g EAST CAROLINA UNIVERSITY   (United States)

Author keywords

active site inhibitors; Acute lymphoblastic leukemia; mTOR; targeted therapy; translation

Indexed keywords

AZD 8055; CD4 ANTIGEN; CD7 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; NAVITOCLAX; OSI 027; PP 103; PP 242; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CD34 SELECTION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA TRANSLATION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CATALYTIC DOMAIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; PHOSPHORYLATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 79955818156     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.20     Document Type: Article

References (47)

1. Herold R, von Stackelberg A, Hartmann R, Eisenreich B, Henze G. Acute lymphoblastic leukemia-relapse study of the Berlin-Frank-furt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol 2004; 22: 569-570.
2. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24: 2005-2013.
3. Zhao WL. Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 2010; 24: 13-21.
4. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 2010; 151: 295-311.
5. Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010; 115: 1735-1745.
6. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122: 3589-3594.
7. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17: 249-261.
8. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29: 3733-3744.
9. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686-1699.
10. Cardoso BA, Martins LR, Santos CI, Nadler LM, Boussiotis VA, Cardoso AA et al. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 2009; 23: 206-208.
11. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008; 118: 3762-3774.
12. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009; 23: 1417-1425.
13. Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010; 24: 239-242.
14. Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008; 453: 529-533. (Pubitemid 351733319)
15. Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS et al. mTOR Activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010; 7: 593-605.
16. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasa-tion. Cancer Cell 2010; 18: 353-366.
17. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009; 69: 3520-3528.
18. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010; 70: 8097-8107.
19. Bhagwat SV, Crew AP. Novel inhibitors of mTORC1 and mTORC2. Curr Opin Investig Drugs 2010; 11: 638-645.
20. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007; 109: 674-682. (Pubitemid 46105969)
21. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z et al. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009; 8: 1473-1483.
22. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22: 1106-1116. (Pubitemid 351833776)
23. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147-160.
24. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010; 116: 4240-4250.
25. Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 2010; 24: 687-698.
26. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38.
27. Hagner PR, Schneider A, Gartenhaus RB. Targeting the transla-tional machinery as a novel treatment strategy for hematologic malignancies. Blood 2010; 115: 2127-2135.
28. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114: 1618-1627.
29. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 2010; 1803: 991-1002.
30. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat 2009; 12: 103-113.
31. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J et al. PML inhibits HIF-1a translation and neoangiogenesis through repression of mTOR. Nature 2006; 442: 779-785. (Pubitemid 44258904)
32. Kubota Y, Hirashima M, Kishi K, Stewart CL, Suda T. Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice. J Clin Invest 2008; 118: 2393-2403. (Pubitemid 351949769)
33. Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 2006; 86: 1221-1232. (Pubitemid 44789912)
34. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 2009; 28: 2581-2592.
35. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14: 2519-2526.
36. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 2010; 128: 509-518.
37. Burger JA, Peled A. CXCR4 antagonists: targeting the microenviron-ment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
38. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
39. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
40. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107: 12469-12474.
41. Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116: 4560-4568.
42. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101. (Pubitemid 40262113)
43. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N et al. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 2008; 283: 31861-31870.
44. Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010; 115: 824-833.
45. Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 2011; 117: 902-914.
46. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
47. Piovan E, Yu J, Real R, Gawinowicz MA, Califano A, Ferrando A. Oncogenic AKT signaling negatively regulates glucocorticoid receptor function to promote glucocorticoid resistance in T cell acute lymphoblastic leukemia. Blood 2010; 116: 11(abstract).